Orthomod LLC recently secured a major technological breakthrough with the issuance of U.S. Patent No. 12721701. This patent, titled ‘Osteoconductive ceramic composite biomaterial utilizing solution-polymerized acrylic carrier and method of manufacture’, introduces a powerful way to integrate structural support with bone healing. Surgeons can now use permanent orthopedic implants with the same load-bearing capacity previously reserved for traditional polymers, while actively promoting natural bone ingrowth.
Advanced Architecture for Orthopedic Implants
The innovation focuses on a new composite biomaterial design for surgical devices. This system uses an engineered acrylic copolymer to form a continuous structural phase. A specialized mineral phase consisting of biphasic calcium phosphate resides within the polymer volume. This material possesses a tailored microporous structure that permits bone to grow directly into the device. A precise formulation ensures the implant maintains mechanical strength while facilitating biological integration. This setup allows for excellent stability during spinal and orthopedic recovery procedures.
Innovation and Regional Recognition
This invention won the Patent of the Month for the Ohio state for the month of October 2026 granted by Swanson Reed due to its high technical merit and significant contribution to medical device engineering in the region. The technology developed by inventors Shawn A. Hunter, David Louis Kirschman, and Dewey J. Weeda is highly innovative because it solves a complex challenge in orthopedics. Standard titanium implants offer high strength but have an elastic modulus far greater than human bone and cause significant imaging artifacts. This novel acrylic and ceramic composite matches the flexibility of natural bone much more closely and is fully visible on X-ray and CT scans without creating metallic distortions. By utilizing a solution-polymerized acrylic carrier, the manufacturing method ensures that the osteoconductive ceramics are properly exposed within complex geometries, making the implant both structurally sound and biologically active.
Eligibility for the U.S. R&D Tax Credit
The practical applications of this patent might be applied to be eligible for an R&D tax credit in the USA. Medical device companies attempting to manufacture these advanced structural biomaterials must undergo systemic experimentation to optimize mineral loading, porosity, and polymer matrix formulations. Testing these new implants for mechanical fatigue, load-bearing longevity, and calcium ion release rates under physiological conditions involves overcoming substantial technical uncertainties. Because these development activities rely on hard sciences and iterative testing to create improved functional products, the engineering and clinical validation efforts align perfectly with the four-part test required by the IRS. Therefore, businesses investing in the commercialization of such osteoconductive composite technologies can often recover a portion of their development costs through federal and state R&D tax incentives.
